曲妥珠单抗和帕妥珠单抗结合多西他赛化疗方案对HER-2阳性乳腺癌术后患者UBE2C及TFF1的影响  

Effects of Trastuzumab and Pertuzumab combined with Docetaxel chemotherapy on the expression of serum UBE2C and TFF1 in postoperative patients with positive HER-2 breast cancer

作　　者：黄秋艳[1] 叶文飞[1] 林庆中[1] 黄丽英[1] Huang Qiuyan;Ye Wenfei;Lin Qingzhong(Department of Breast Surgical Oncology,Fujian Medical University Cancer Hospital,Fujian Cancer Hospital,Fuzhou 350014)

机构地区：[1]福建医科大学附属肿瘤医院福建省肿瘤医院乳腺肿瘤外科,福建福州350014

出　　处：《中国现代医药杂志》2022年第7期44-48,共5页Modern Medicine Journal of China

摘　　要：目的探究曲妥珠单抗(H)和帕妥珠单抗(P)结合多西他赛(T)化疗方案对HER-2阳性乳腺癌术后患者血清人类泛素偶联酶E2C(UBE2C)及三叶因子Ⅰ(TFF1)表达的影响。方法选取2020年10月~2021年10月在我院接受化疗的HER-2阳性乳腺癌术后患者76例,按化疗方案不同分成两组,其中38例予以TH方案辅助化疗,作为对照组,38例在对照组基础上加用帕妥珠单抗治疗(THP),作为观察组。对比两组患者治疗前后UBE2C及TFF1的表达水平、生活质量及不良反应发生情况。结果观察组治疗后UBE2C水平为(0.51±0.12)mg/ml、TFF1水平为(2.01±0.24)mg/ml,低于对照组的(0.63±0.13)mg/ml、(2.38±0.26)mg/ml,差异有统计学意义(t=4.181、6.446,P<0.05);观察组治疗后癌症患者生命质量量表(FACT-G)各维度评分均较对照组高,差异有统计学意义(P<0.05);观察组不良反应发生率为28.95%,与对照组的26.32%比较差异无统计学意义(χ^(2)=0.066,P>0.05)。结论THP方案辅助化疗应用于HER-2阳性乳腺癌术后患者中可有效降低UBE2C及TFF1表达水平,帕妥珠单抗可能通过下调UBE2C及TFF1表达进而提高疗效。Objective To investigate the effects of trastuzumab(H)and pertuzumab(P)combined with docetaxel(T)chemotherapy on the expression of human ubiquitin conjugating enzyme E2C(UBE2C)and trefoil factor familyⅠ(TFF1)in serum of postoperative patients with positive HER-2 breast cancer.Methods 76 postoperative patients with positive HER-2 breast cancer who were received chemotherapy in our hospital from Oct 2020 to Oct 2021 were selected,and divided into two groups according to different chemotherapy regimens.38 cases were treated with TH regimen as the control group,38 cases were treated with THP regimen as the observation group.The expression levels of UBE2C and TFF1,quality of life and the adverse reactions were compared between the two groups before and after treatment.Results After treatment,the level of UBE2C in the observation group was(0.51±0.12)mg/ml,and the level of TFF1 was(2.01±0.24)mg/ml,which were lower than those in the control group(0.63±0.13)mg/ml and(2.38±0.26)mg/ml,the difference were statistically significant(t=4.181,6.446,P<0.05).In the observation group,the scores of each dimension of cancer patients’quality of life scale(FACT-G)after treatment were higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was 28.95%,and there was no significant difference compared with 26.32%in the control group(χ^(2)=0.066,P>0.05).Conclusion THP regimen can effectively reduce the expression levels of UBE2C and TFF1 in postoperative patients with positive HER-2 breast cancer,which predicts that pertuzumab can improve the efficacy by reducing the expression of UBE2C and TFF1.

关 键 词：曲妥珠单抗 帕妥珠单抗 多西他赛 乳腺癌 术后化疗 

分 类 号：R737.9[医药卫生—肿瘤]